Multimodal prognostic models for bladder urothelial carcinoma: uroplakin III combined with serum and demographic data
{{output}}
Background: Bladder urothelial carcinoma (BUC) remains a highly recurrent and heterogeneous malignancy. Accurate postoperative risk stratification is crucial to guide adjuvant therapy decisions. We hypothesized that integrating U... ...
